Literature DB >> 9497069

Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants.

E Pelosi1, G B Mulamba, D M Coen.   

Abstract

We compared the penciclovir susceptibilities and pathogenesis phenotypes of mutants of Herpes simplex virus type 1 that are resistant to acyclovir and/or foscarnet. The mutants, which were derived from laboratory strain KOS, included six DNA polymerase mutants, a thymidine kinase negative mutant, a thymidine kinase partial mutant, and a double mutant. Two of four polymerase mutants not previously examined for penciclovir susceptibility exhibited modest resistance to this drug. A thymidine kinase negative mutant exhibited approximately 20-fold resistance while a thymidine kinase partial mutant was penciclovir-sensitive. Following intracerebral inoculation of 7-week old CD1 mice, the mutants ranged from exhibiting near wild-type neurovirulence (thymidine kinase partial) to modest attenuation (e.g. thymidine kinase negative) to more severe attenuation. Following corneal inoculation, three polymerase mutants exhibited modest deficits (relative to those of thymidine kinase negative mutants) in their abilities to replicate acutely in the ganglion and reactivate from latency. For mutant AraA(r)13, the deficit in ganglionic replication was shown to be due to its polymerase mutation by analysis of recombinant viruses derived by marker rescue. These results may have implications for issues of penciclovir action and resistance, for drug resistance in the clinic, and for the interactions of herpes viruses with the peripheral and central nervous systems.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9497069     DOI: 10.1016/s0166-3542(97)00054-5

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  11 in total

Review 1.  Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  Characterization of herpes simplex virus type 1 thymidine kinase mutants selected under a single round of high-dose brivudin.

Authors:  Graciela Andrei; Jan Balzarini; Pierre Fiten; Erik De Clercq; Ghislain Opdenakker; Robert Snoeck
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

3.  The enzymological basis for resistance of herpesvirus DNA polymerase mutants to acyclovir: relationship to the structure of alpha-like DNA polymerases.

Authors:  L Huang; K K Ishii; H Zuccola; A M Gehring; C B Hwang; J Hogle; D M Coen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

4.  Effects of antiviral usage on transmission dynamics of herpes simplex virus type 1 and on antiviral resistance: predictions of mathematical models.

Authors:  M Lipsitch; T H Bacon; J J Leary; R Antia; B R Levin
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

5.  Thymidine Kinase-Negative Herpes Simplex Virus 1 Can Efficiently Establish Persistent Infection in Neural Tissues of Nude Mice.

Authors:  Chih-Yu Huang; Hui-Wen Yao; Li-Chiu Wang; Fang-Hsiu Shen; Sheng-Min Hsu; Shun-Hua Chen
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

6.  Characterization of herpes simplex viruses selected in culture for resistance to penciclovir or acyclovir.

Authors:  R T Sarisky; M R Quail; P E Clark; T T Nguyen; W S Halsey; R J Wittrock; J O'Leary Bartus; M M Van Horn; G M Sathe; S Van Horn; M D Kelly; T H Bacon; J J Leary
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

7.  Differential mutation patterns in thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 clones passaged in the presence of acyclovir or penciclovir.

Authors:  Tatsuo Suzutani; Ken Ishioka; Erik De Clercq; Kei Ishibashi; Hisatoshi Kaneko; Toshihiko Kira; Koh-Ichi Hashimoto; Masahiro Ogasawara; Katsuki Ohtani; Nobutaka Wakamiya; Masayuki Saijo
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

8.  Sodium lauryl sulfate increases the efficacy of a topical formulation of foscarnet against herpes simplex virus type 1 cutaneous lesions in mice.

Authors:  J Piret; A Désormeaux; H Cormier; J Lamontagne; P Gourde; J Juhász; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

Review 9.  Tolerability of treatments for postherpetic neuralgia.

Authors:  Mark W Douglas; Robert W Johnson; Anthony L Cunningham
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

10.  Development and evaluation of a host-targeted antiviral that abrogates herpes simplex virus replication through modulation of arginine-associated metabolic pathways.

Authors:  Maria Dulfary Sanchez; Augusto C Ochoa; Timothy P Foster
Journal:  Antiviral Res       Date:  2016-05-15       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.